

			Sale estimates million DKR				
	Royalty	Peaksale	2021	2022	2023	2024	2025
Daratumumab (CD38) MM	17%	10B\$USD	6500	7800	8500	9200	9900
AL Amyloidosis (Dara)							
Non MM blod cancers : phase 2 (Dara)							
Ofatumumab (CD20) MS	10%	2.5B\$USD	250	500	750	1000	1250
Teprotumumab (IGF-1R) Thyroid ey edisease	8%	3.5B\$USD	100	200	400	800	1736
Amivantamab	10%	1B\$USD	75	155	310	620	620
Tisotumab Vedotin (Cervical cancer)	50/50	500M\$USD	25	100	150	200	250
Ovarian Cancer	50/50						
Solid tumors	50/50						
Epcoritamab	50/50	5B\$USD	0	1000	2000	4000	8000
HexaBody-CD38							
<b>Total</b>			<b>6950</b>	<b>9755</b>	<b>12110</b>	<b>15820</b>	<b>21756</b>